Pharmacological analysis of extracellular dopamine and metabolites in the striatum of conscious as/agu rats, mutants with locomotor disorder

Neuroscience

Volumn 100, Issue 1, 2000, Pages 45-52

  Campbell, J M ^a   Gilmore, D P ^a   Russell, D ^a   Growney, C A ^a   Favor, G ^a   Kennedy, A K ^a   Davies, R W ^a   Payne, A P ^a   Stone, T W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Amphetamine; Clorgyline; Dopamine; Microdialysis; Nomifensine; Striatum

Indexed keywords

AMPHETAMINE; BENSERAZIDE PLUS LEVODOPA; CLORGYLINE; DOPAMINE; NOMIFENSINE; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CORPUS STRIATUM; DOPAMINE RELEASE; LOCOMOTION; METABOLITE; MOTOR DYSFUNCTION; MUTANT; PRIORITY JOURNAL;

AMPHETAMINE; ANIMALS; CLORGYLINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE UPTAKE INHIBITORS; EXTRACELLULAR SPACE; LEVODOPA; MALE; MICE; MICE, MUTANT STRAINS; MONOAMINE OXIDASE INHIBITORS; MOVEMENT DISORDERS; NOMIFENSINE; POTASSIUM; REFERENCE VALUES;

EID: 0034618821     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00251-7     Document Type: Article

References (52)

1. Abercrombie E.D., Bonatz A.E., Zigmond M.J. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525:1990;36-44.
2. Altar C.A., Marien M.R. Preservation of dopamine release in denervated striatum. Neurosci. Lett. 96:1989;329-334.
3. Arbuthnott G.W., Fairbrother I.S., Butcher S.P. Dopamine release and metabolism in the rat striatum: an analysis by 'in vivo' brain microdialysis. Pharmac. Ther. 48:1990;281-293.
4. Benveniste H. Brain microdialysis. J. Neurochem. 52:1989;1667-1679.
5. Braestrup C., Scheel-Kruger J. Methylphenidate-like effects of the new antidepressant drug nomifensine (HOE984). Eur. J. Pharmac. 38:1976;305-312.
6. Brannan T., Prikhojan A., Yahr M.D. Elevated striatal dopamine levels following administration of D-dopa and its alpha-keto acid metabolite DHPPA: behavioural and physiological studies in vivo in the rat. Brain Res. 718:1996;165-168.
7. Brannan T., Prikhojan A., Yahr M.D. An in vivo comparison of the capacity of striatal versus extrastriatal brain regions to form dopamine from exogenously administered L-dopa. J. neural Transm. 103:1996;1287-1294.
8. Brannan T., Prikhojan A., Martinez-Tica J., Yahr M.D. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J. neural Transm. 10:1995;79-89.
9. Broch O.J. In vivo effects of benztropine and nomifensine on dopamine and noradrenaline terminals in rat brain. Eur. J. Pharmac. 58:1979;419-424.
10. Bunney B.S., Aghajanian G.K., Roth R.H. Comparison of the effects of L-DOPA, amphetamine and apomorphine on rat dopaminergic neurones. Nature New Biol. 245:1973;123-125.
11. Butcher S.P., Fairbrother I.S., Kelly J.S., Arbuthnott G.W. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 50:1988;346-355.
12. Butcher S.P, Fairbrother I.S., Kelly J.S., Arbuthnott G.W. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 55:1990;981-988.
13. Campbell J.M., Payne A.P., Gilmore D.P., Byrne J.E., Russell D., McGadey J., Clarke D.J., Davies R.W, Sutcliffe R.G. Neostriatal dopamine depletion and locomotor abnormalities due to the albino Swiss rat agu mutation. Neurosci. Lett. 213:1996;173-176.
14. Campbell J.M., Payne A.P., Gilmore D.P., Russell D., McGadey J., Clarke D.J., Branton R., Davies R.W., Sutcliffe R.G. Age changes in dopamine levels in the corpus striatum of albino Swiss (AS) and as/agu mutant rats. Neurosci. Lett. 239:1997;54-56.
15. Campbell J.M., Gilmore D.P., Russell D., Growney C.A., Favor G., Weir J., Stone T.W., Payne A.P. Extracellular levels of dopamine and its metabolite 3,4-dihydroxy-phenylacetic acid measured by microdialysis in the corpus striatum of conscious AS/AGU mutant rats. Neuroscience. 85:1998;323-325.
16. Carswell H.V.O., Graham D.I., Stone T.W. Kainate-evoked release of adenosine from the hippocampus of the anaesthetised rat: possible involvement of free radicals. J. Neurochem. 68:1997;240-247.
17. Cho S., Duchemin A.M., Heff N.H., Hadjiconstantinou M. Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monamine oxidase-A. Eur. J. Pharmac. 314:1996;51-59.
18. Clarke D.J., Payne A.P. Neuroanatomical characterisation of a new mutant rat with dopamine depletion in the substantia nigra. Eur. J. Neurosci. 6:1994;885-888.
19. Cumming P., Brown E., Damsma G., Fibiger H. Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: an in vivo microdialysis study. J. Neurochem. 59:1992;1905-1914.
20. Di Monte D.A., DeLanney L.E., Irwin I., Royland J.E., Chan P., Jakowec M.W., Langston J.W. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res. 738:1996;53-59.
21. Dyck L.E., Durden D.A., Boulton A.A. Effects of monoamine oxidase inhibitors on the acid metabolites of some trace amines and of dopamine in the rat striatum. Biochem. Pharmac. 45:1993;1317-1322.
22. Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48:1996;1-19.
23. Elverfors A., Nissbrandt H. Effects of D-amphetamine on dopaminergic neurotransmission: a comparison between the substantia nigra and the striatum. Neuropharmacology. 31:1992;661-670.
24. Finberg J.P.M., Wang J., Goldstein D.S., Kopin I.J., Bankiewicz K.S. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J. Neurochem. 65:1995;1213-1220.
25. Hastings T.G., Zigmond M.J. Loss of dopaminergic neurons in Parkinsonism: possible role of reactive dopamine metabolites. J. neural Transm., Suppl. 49:1997;103-110.
26. Hunt P., Kannengiesser M.-H., Raynaud J.-P. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J. Pharm. Pharmac. 26:1974;370-373.
27. Hurd Y.L., Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur. J. Pharmac. 166:1989;251-260.
28. Imperato A., DiChiara G. Trans-striatal dialysis coupled to reverse phase HPLC with electrochemical detection. A new method for the study of the in vivo release of endogenous dopamine and metabolites. J. Neurosci. 4:1984;966-977.
29. Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18:1998;1979-1986.
30. Juorio A.V., Paterson I.A., Zhu M.Z. Dopamine metabolism in the guinea-pig striatum: role of monoamine oxidase A and B. Eur. J. Pharmac. 254:1994;213-220.
31. Karoum F., Chrapusta S.J., Brinjak R., Hitri A., Wyatt R.J. Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br. J. Pharmac. 113:1994;1391-1399.
32. Kumagae Y., Matsui Y., Iwata N. Deamination of norepinephrine, dopamine and serotonin by type A monamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jap. J. Pharmac. 55:1991;121-128.
33. Mannisto P.T., Tuomainen P. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Archs Pharmac. 344:1991;412-418.
34. Miller H.H., Shore P.A., Clarke D.E. In vivo monoamine oxidase inhibition by amphetamine. Biochem. Pharmac. 29:1980;1347-1354.
35. MolinaHolgado E., Dewar K.M., Descarries M., Reader T.A. Altered dopamine and serotonin metabolism in the dopamine-denervated and serotonin-hyperinnervated neostriatum of adult rat after neonatal 6-hydroxydopamine. J. Pharmac. exp. Ther. 270:1994;713-721.
36. Nakachi N., Kiuchi Y., Inagaki M., Inazu M., Yamazaki Y., Oguchi K. Effect of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur. J. Pharmac. 281:1995;195-203.
37. Nakano M., Hitomi E., Mizuno T. Age-related changes in the metabolism of neurotransmitters and the effect of scavengers: an in vivo microdialysis study. Archs. Geront. Geriat. 18:1994;171-176.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic, New York.
39. Payne A.P, Sutcliffe R.G., Campbell J.M., Favor G., Russell D., Bennett N.K., Clarke D.J., Branton R., Wayne Davies R., Simpson E., Tsang C., Baxendale R.H. Disordered locomotion in the AS/AGU mutant rat and the effects of L-dopa or fetal midbrain grafts. Movement Disord. 13:1998;832-834.
40. Scheel-Kruger J. Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of catecholamines in the rat brain. Eur. J. Pharmac. 14:1971;47-59.
41. Scott D.L., Campbell J.M., Clarke D.J., Gilmore D.P., Payne A.P. Noradrenergic deficits in the locus coeruleus of AS/AGU rats. Eur. J. Neurosci., Suppl. 7:1994;96.
42. Sharp T., Zetterstrom T., Ungerstedt U. An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral microdialysis. J. Neurochem. 47:1986;113-122.
43. Shi W.-X. and Bunney B. S. (1996) Antipsychotic drug-induced depolarization inactivation of dopaminergic neurones - evidence, mechanism and significance. In CNS Neurotransmitters and Neuromodulators. Dopamine (ed. Stone T. W.). CRC, Boca Raton, FL.
44. Skutella T., Schwarting R.K.W., Huston J.P., Sillaber I., Probst J.C., Holsboer F., Spanagel R. Infusions of tyrosine hydroxylase antisense oligodeoxynucleotide into substantia nigra of the rat: effects on tyrosine hydroxylase mRNA and protein content, striatal dopamine release and behaviour. Eur. J. Neurosci. 9:1997;210-220.
45. Stewart A.A., Campbell J.M., McGadey J., Clarke D.J., Gilmore D.P., Payne A.P. Serotonergic deficits in the raphe nuclei of AS/AGU rats. J. Anat. 185:1994;702.
46. Wachtel A.R., Abercrombie E.D. L-DOPA-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of MAO A and B inhibitors. J. Neurochem. 63:1994;108-117.
47. Weseman W., Grote C., Clement H.W., Block F., Sontag K.H. Functional studies on monoaminergic transmitter release in Parkinsonism. Prog. Neuropsychopharmac. biol. Psychiat. 17:1993;487-499.
48. Westfall T.C., Naes L., Paul C. Relative potency of dopamine agonists on autoreceptor function in various brain regions of the rat. J. Pharmac. exp. Ther. 224:1983;199-205.
49. Xu K., Dluzen D.E. L-DOPA modulation of corpus striatal dopamine and DOPAC output from intact and 6-hydroxydopamine lesioned rats. J. neural Transm. 103:1996;1295-1305.
50. Zetterstrom T., Sharp T., Marsden C.A., Ungerstedt U. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after D-amphetamine. J. Neurochem. 41:1983;1769-1773.
51. Zetterstrom T., Herrera-Marschitz M., Ungerstedt U. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine-denervated rats using intracerebral dialysis. Brain Res. 376:1986;1-7.
52. Zhang W.Q., Tilson H.A., Nanry K.P., Hudson P.M., Hong J.S., Stachowiak M.K. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res. 461:1988;335-342.